Mostrando 2 resultados de: 2
Filtros aplicados
Área temáticas
Enfermedades(2)
Área de conocimiento
Farmacología(1)
Año de Publicación
2022(2)
Origen
scopus(2)
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile
ReviewAbstract: inTrodUCTion: The management of non-metastatic castration-resistant prostate cancer (nmCrpC) has undPalabras claves:Apalutamide, Castration, Darolutamide, Enzalutamide, Network meta-analysis, prostatic neoplasmsAutores:Briganti A., Diego M. Carrión, Egawa S., Esperto F., Fiori C., Grossmann N.C., Katayama S., Kimura T., Laukhtina E., Mori K., Mostafaei H., Motlagh R.S., Papalia R., Ploussard G., Pradere B., Quhal F., Rajwa P., Schuettfort V.M., Shariat S.F.Fuentes:scopusThe Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
ArticleAbstract: Background: There might be differential sensitivity to neoadjuvant chemotherapy (NAC) in patients wiPalabras claves:bladder cancer, Neoadjuvant chemotherapy, Primary, Response, Secondary, SurvivalAutores:Alvarez-Maestro M., Brönimann S., De Berardinis E., del Giudice F., Di Maida F., Di Trapani E., Diego M. Carrión, D’Andrea D., Filippot R., Grisay G., Hendricksen K., Krajewski W., Laukhtina E., Maggi M., Mari A., Mertens L.S., Moschini M., Paulnsteiner D., Pichler R., Pradere B., Shariat S.F., Soria F., Vallet S., van Rhijn B.W.G.Fuentes:scopus